Myriad to Present Seven Clinical Studies at the Annual Clinical Genetics Meeting
March 25 2014 - 7:05AM
Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that results
from seven clinical studies will be presented at the upcoming
American College of Medical Genetics (ACMG) annual meeting, which
will be held Mar. 25-Mar.29, 2013 in Nashville, Tennessee.
"We believe clinical research is vital to advance the science
surrounding hereditary cancer and genetic testing, and we are
committed to sharing timely and accurate information about our
research with the scientific and medical communities," said Richard
Wenstrup, chief medical officer at Myriad. "Myriad will continue to
be a pioneer in hereditary cancer testing, especially as we look to
improve patient care with our next-generation, myRisk™ Hereditary
Cancer panel."
Summaries of three of Myriad's key poster presentations at ACMG
surrounding Myriad's testing process and the Company's myVision™
variant classification program are presented below:
|
2014 ACMG – KEY POSTER
PRESENTATIONS |
|
|
Title: |
Align-GVGD, SIFT, Polyphen, MAPP-MMR,
Grantham Analysis and Condel are weak |
|
predictors of the clinical significance
of missense variants. |
Presenter: |
Iain Kerr |
Date: |
Friday, Mar. 28, 10:30 am to 12:00 pm
CDT (Poster 266) |
Summary: |
This study analyzes several commonly
utilized variant classification algorithms and |
|
compares their performance to Myriad's
proprietary variant classification program. The |
|
study found that the accuracy of these
algorithms was substantially lower than the |
|
traditionally accepted threshold for
clinical confidence. |
|
|
|
|
Title: |
Determining the clinical significance of
silent BRCA1 and BRCA2 sequencing variants. |
Presenter: |
Karla Bowles |
Date: |
Friday, Mar. 28, 10:30 am to 12:00 pm
CDT (Poster 302) |
Summary: |
Sequencing analysis of the BRCA1 and
BRCA2 genes may identify mutations that are |
|
predicted to be translationally silent.
This study describes a testing algorithm used by |
|
Myriad to determine the possible
pathogenicity of silent mutations. |
|
|
|
|
Title: |
Assessment of laboratory-based quality
control processes to ensure appropriate |
|
utilization of genetic testing for
hereditary cancer risk. |
Presenter: |
Serenedy Smith |
Date: |
Thursday, Mar. 27, 10:30 am to 12:00 pm
CDT (Poster 165) |
Summary: |
This study evaluated BRACAnalysis® and
Colaris® case submissions to evaluate whether |
|
they met established clinical indications
for testing based on patient histories. The study |
|
found that only 0.5 percent of test
orders lacked apparent clinical risk factors for the |
|
ordered test and 93 percent met
established clinical indications for testing consistent
with |
|
NCCN 2012 practice guidelines. |
|
|
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic company
dedicated to making a difference in patients' lives through the
discovery and commercialization of transformative tests to assess a
person's risk of developing disease, guide treatment decisions and
assess risk of disease progression and recurrence. Myriad's
molecular diagnostic tests are based on an understanding of the
role genes play in human disease and were developed with a
commitment to improving an individual's decision making process for
monitoring and treating disease. Myriad is focused on strategic
directives to introduce new products, including companion
diagnostics, as well as expanding internationally. For more
information on how Myriad is making a difference, please visit the
Company's website: www.myriad.com.
Myriad, the Myriad logo and Prolaris, Myriad myPath, Myriad
myPlan, Myriad myRisk, are trademarks or registered trademarks of
Myriad Genetics, Inc. in the United States and foreign countries.
MYGN-F, MYGN-G.
Safe Harbor Statement
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements relating to results from seven
clinical studies being presented at the upcoming American College
of Medical Genetics (ACMG) annual meeting; the myRisk Hereditary
Cancer panel improving patient care; and the Company's strategic
directives under the caption "About Myriad Genetics." These
"forward-looking statements" are management's present expectations
of future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially
and adversely from those described in the forward-looking
statements. These risks include, but are not limited to: the
risk that sales and profit margins of our existing molecular
diagnostic tests and companion diagnostic services may decline or
will not continue to increase at historical rates; risks related to
changes in the governmental or private insurers reimbursement
levels for our tests; the risk that we may be unable to develop or
achieve commercial success for additional molecular diagnostic
tests and companion diagnostic services in a timely manner, or at
all; the risk that we may not successfully develop new markets for
our molecular diagnostic tests and companion diagnostic services,
including our ability to successfully generate revenue outside the
United States; the risk that licenses to the technology underlying
our molecular diagnostic tests and companion diagnostic services
tests and any future tests are terminated or cannot be maintained
on satisfactory terms; risks related to delays or other problems
with operating our laboratory testing facilities; risks related to
public concern over our genetic testing in general or our tests in
particular; risks related to regulatory requirements or enforcement
in the United States and foreign countries and changes in the
structure of the healthcare system or healthcare payment systems;
risks related to our ability to obtain new corporate collaborations
or licenses and acquire new technologies or businesses on
satisfactory terms, if at all; risks related to our ability to
successfully integrate and derive benefits from any technologies or
businesses that we license or acquire; risks related to increased
competition and the development of new competing tests and
services; the risk that we or our licensors may be unable to
protect or that third parties will infringe the proprietary
technologies underlying our tests; the risk of patent-infringement
claims or challenges to the validity of our patents; risks related
to changes in intellectual property laws covering our molecular
diagnostic tests and companion diagnostic services and patents or
enforcement in the United States and foreign countries, such as the
Supreme Court decision in the lawsuit brought against us by the
Association for Molecular Pathology et al; risks of new, changing
and competitive technologies and regulations in the United States
and internationally; and other factors discussed under the heading
"Risk Factors" contained in Item 1A of our most recent Annual
Report on Form 10-K filed with the Securities and Exchange
Commission, as well as any updates to those risk factors filed from
time to time in our Quarterly Reports on Form 10-Q or Current
Reports on Form 8-K. All information in this press release is as of
the date of the release, and Myriad undertakes no duty to update
this information unless required by law.
CONTACT: Media Contact:
Ron Rogers
(801) 584-3065
rrogers@myriad.com
Investor Contact:
Scott Gleason
(801) 584-1143
sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2023 to Apr 2024